

A METHOD FOR EARLY DIAGNOSIS OF PANCREATIC CANCER



Karolina Kasparova
Centre for Technology and Knowledge Transfer
karolina.kasparova@upce.cz

BioVaria 2018, Munich
23 – 24 April 2018

Well-known victims of pancreatic cancer



Luciano Pavarotti (1)
diagnosed 2006, died 2007



Patrick Swayze (2)
diagnosed 2008, died 2009



Steve Jobs (3)
diagnosed 2004, died 2011

91% of pancreatic cancer patients die – **Diagnosed in an Advanced and Incurable Stage!!**


Screening tests for breast cancer, prostate cancer, colon cancer have saved millions of lives over the last 20 years.

Highly Sensitive and Specific Screening Tools URGENTLY NEEDED!!



PANCREATIC CANCER IN NUMBERS / American Cancer Society

- **91%** mortality rate; **2,019,863** people died of **PC** since 1971
- Estimated new cases in US, 2018 - 55,440 people
- Estimated deaths in US, 2018 - 44,330 people
- Average PC 5-year survival is <5%



Stage	Diagnosed	5 Year Survival Rate
Stage 0	7%	20% +
Stage I	7%	20% +
Stage II	26%	8.2%
Stage III	26%	8.2%
Stage IV	52%	1.8%

Source (4)



SELECTIVE SCREENING OF HIGH RISK INDIVIDUALS

Potential intervention

Risk assessment and prevention


← Screening →

Surgical resection and adjuvant therapy


← Palliative chemotherapy, other therapies →

Natural history of pancreatic cancer development and progression


PRECURSOR LESIONS



Early stage PC



Late stage PC



Level of tumor marker production (specific and non-specific)

Mutant DNA, proteins, microRNAs, modified proteins, methylated DNA, peptides, cytokines, autoantibodies, etc

Clinical presentation

100%
Probability of symptoms
0


Asymptomatic

Symptomatic



Source (5)

OUR APPROACH = MS LIPIDOMIC QUANTITATION



Biological fluid

- 10-25µl of sample

MS based analysis

- UHPLC/MS, UHPSFC/MS
- MALDI/MS
- Shotgun MS
- lipidome dysregulation – up to **400 species**
- analysis time = **14 minutes**

Data

processing

- own software
- MDA

Statistical


Analysis

- **early stage** dysregulation – PanIN,T0

	m/z	sample 1	sample 2	sample 3	...
raw data	756.5504	18405	19025	64662	
	758.5683	3474606	3367948	6039620	
	760.5817	1806527	1766268	2718620	
	762.5883	88877	90202	123825	
LipidQuant					
Identification	m/z _{accurate}	lipids			
	756.5538	PC(34:3)			
	758.5695	PC(34:2)			
	760.5851	PC(34:1)			
	762.6008	PC(34:0)			
Isotopic Correction					
Quantification	m/z	sample 1	sample 2	sample 3	
	PC(34:3)	16.56	16.85	47.55	
	PC(34:2)	3124.69	2980.37	4435.52	
	PC(34:1)	1236.33	1192.75	1446.56	
	PC(34:0)				




Pancreatic Cancer: UHPSFC + Shotgun (Males)



Model works well for all stages including early stages T1 and T2

Pancreatic Cancer: UHPSFC + Shotgun (Females)



Model works well for all stages including early stages T1 and T2

COMPARISON WITH EXISTING SOLUTIONS

recommended by International Cancer of the Pancreas Screening (CAPS) Consortium summit

Selective screening of individuals at increased risk based on their family history or identifiable genetic predisposition is considered very worthwhile, because pancreatic neoplasia detected early is potentially curable.

Further competitor method could be Immunovia's IMMray™ PanCan-d test - platform based on antibody microarray analysis, still in validation.

Method	Invasive	Sensitivity	Specificity	Radiation or magnetic field exposure	Operator dependance	Price per test or analysis in Europe, US more expensive
EUS	✓	95 %	80 %	x	✓	from 125 EUR
MRI/MRCP	x	>83 %	>8 %	✓	x	from 200 EUR
MS Lipidomics	x	>95 %	>95 %	x	x	expected below 40 EUR



IP & DEVELOPMENT STATUS



- EP application was filed in January 2018. 2nd EP application in preparation, filing expected May 2018.
- current results derived from clinical validation covering about **1,000** human samples of healthy volunteers and cancer patients
- methodology could discriminate pancreatic cancer patients from healthy controls with **>95%** accuracy
- the sample throughput is **10,000 samples per year** and one MS system
- validated in line with recommendations of **FDA and EMEA**

Icon made by Freepik – Flaticon.com



COMMERCIAL OPPORTUNITY



Worldwide Unmet Need

The global pancreatic cancer therapeutics & diagnostics market is expected to witness a CAGR 5.6% during the forecast period, 2018-2023.

Based on test, the market has been segmented into:

- Imaging test, Biopsy, Blood test

Based on end user, global pancreatic cancer diagnostics market is segmented into:

- Hospitals, Oncology Institutes, Diagnostic Centres



FURTHER DEVELOPMENT

3 months

Current model adoption
by clinical lipidomic lab!

The methodology is available for licensing and further development.

Technology development,
ERC CZ funding

2013 - 2018

Model improvements, further clinical validation, various
effects on variability, model for further diseases, urine
samples analysis, etc.

2018 - 2023

2 mil EUR spent

3 mil EUR expected costs



RESEARCH TEAM

prof. Holčapek

- Mass Spectrometry Group @ University of Pardubice

<http://holcapek.upce.cz/>

ACKNOWLEDGEMENTS

for financial support



EUROPEAN UNION
European Structural and Investment Funds
Operational Programme Research,
Development and Education



SOURCES

1. Luciano Pavarotti, Source: <https://www.thefamouspeople.com/profiles/luciano-pavarotti-3443.php>
2. Patrick Swayze, Source: <https://www.thefamouspeople.com/profiles/patrick-swayze-6214.php>
3. Steve Jobs, Source: <https://www.google.cz/amp/s/www.slashgear.com/steve-jobs-1973-job-application-heads-to-auction-for-50k-24520895/amp/?source=images>
4. Terese Winslow LLC, 2005, Medical And Scientific Illustration
5. 2011, AACR (American Association for Cancer Research)

